Novel treatments for acute myeloid leukemia #FIMM_UH
Helsinki, Finland
Joined October 2021
- Tweets16
- Following101
- Followers81
- Likes71
Kontro Lab retweeted
This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring
Read more in depth 👉bit.ly/3Lllpo9
Our latest @Hemasphere_EHA study from @FIMM_UH defines key signatures of #venetoclax + hypomethylating agent #resistance in #AML and highlights strategies for targeting resistant disease.
Read more: doi.org/10.1002/hem3.70282
Kontro Lab retweeted
Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB)
@myESMO @OncoAlert @Daver_Leukemia @Dr_AmerZeidan
Kontro Lab retweeted
1/4
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial
New study by @LabKontro and colleagues – study highlights 👇
Ex vivo venetoclax sensitivity identified treatment responders and correlated with improved outcomes and prolonged survival. Groundbreaking results from the VenEx trial with the Finnish AML Group, @helsinkiuni and @FIMM_UH published now in @BloodJournal
VenEx trial showed that ex vivo drug sensitivity is beneficial for selecting patients with R/R or sAML for venetoclax-azacitidine therapy. ow.ly/XpL350UMeJB #clinicaltrialsandobservations #myeloidneoplasia
Kontro Lab retweeted
Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy.
New @LabKontro results allow treatments to be tailored to those who are most likely to benefit.
📰@HUS_fi:
hus.fi/en/newsroom/drug-sens…
ALT Tanja Ruokoranta, Ida Vänttinen and Mika Kontro working in a cell culture room wearing white laboratory coats. Photo: Ville Männikkö/HUS
Kontro Lab retweeted
Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle.
@LabKontro tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille.
📰@HUS_fi: hus.fi/ajankohtaista/laakehe…
ALT Tutkijat Tanja Ruokoranta, Ida Vänttinen ja Mika Kontro työskentelemassä soluviljelylaboratoriossa valkoiset takit päällä. Kuva: Ville Männikkö / HUS
Dr. Mika Kontro from @KontroLab discussed the latest advances in functional screening during the Multi-Omics Driven Precision Hematology Scientific Symposia at #ASH23. The VenEx trial indicates the efficacy of ex vivo venetoclax testing for predicting VEN+AZA responses in AML.
Kontro Lab retweeted
Meet our K. Albin Johansson Cancer Researcher @hkuusanm. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in @LabKontro. Read more 👇syopainstituutti.com/researc…
Kontro Lab retweeted
A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & @hkuusanm.
helsinki.fi/en/hilife-helsin…
Kontro Lab retweeted
1/ Excited to share our study with @ollidufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal
doi.org/10.1182/blood.202101…
Our newest paper "Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" is now published and accessible @Haematologica
haematologica.org/article/vi…
Kontro Lab retweeted
Ex vivo venetoclax sensitivity predicts responses in both de novo and s/R/R AML patients @LabKontro #ASH22
Excellent talk by @josephsaad95 on NAMPT inhibitors in AML with monosomy 7/del(7q) yesterday at #ASH22!
Ex vivo drug sensitivity testing predicts venetoclax+azacitidine treatment responses in AML. VenEx trial interim results presented at #ASH21
